Nevanac®
Nepafenac 0.1% · ophthalmic suspension
NSAID
Approved uses
Pain and inflammation associated with cataract surgery
One drop TID beginning 1 day before surgery, on the day of surgery, and through the first 2 weeks postoperatively.
Cells and flare clear completely by day 14 in 63%, and over 80% are pain free at every visit.
OFF-LABELNot in the FDA label for this product
Prevention of macular edema after cataract surgery in diabetic retinopathy (off-label)
Trial regimen: one drop TID beginning 1 day before surgery and continued through day 90, on top of tobramycin-dexamethasone QID for the first 2 weeks. Exceeds the labeled 14-day postoperative duration.
RCT · n=175 · acuity gain NS
Randomized, double-masked, vehicle-controlled multicenter trial in 175 patients with nonproliferative diabetic retinopathy: macular edema, defined as a 30% or greater rise in central subfield thickness, within 90 days of surgery in 5.0% (95% CI 1.4 to 12.3) versus 17.5% on vehicle (95% CI 9.9 to 27.6), p=0.01. The day 90 mean BCVA gain favored nepafenac but was not statistically significant (17.7 versus 14.3 letters, p=0.14).
Ocular pain after photorefractive keratectomy (off-label)
Trial regimen: one drop TID in the treated eye through postoperative day 2.
RCT · n=35 · no untreated arm
Contralateral-eye randomized comparative study in 35 patients, 0.1% TID in one eye versus nepafenac 0.3% once daily in the fellow eye through day 2, found no difference in pain scores, subepithelial haze, or visual acuity. There was no untreated or vehicle arm, so this establishes equivalence between the two concentrations, not efficacy over no treatment.
Contraindications
Previously demonstrated hypersensitivity to any of the ingredients in the formula or to other non-steroidal anti-inflammatory drugs (NSAIDs)
0.1% sterile ophthalmic suspension, 3 mL in a 4 mL bottle
Nonsteroidal anti-inflammatory prodrug; after topical ocular dosing it penetrates the cornea and is converted by ocular tissue hydrolases to amfenac, an NSAID. Amfenac is thought to inhibit the action of prostaglandin H synthase (cyclooxygenase), an enzyme required for prostaglandin production.
Warnings & Precautions
- Corneal effects: Topical NSAIDs may cause keratitis, and continued use in some susceptible patients may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation. These events may be sight threatening; patients with evidence of corneal epithelial breakdown should immediately discontinue use and be closely monitored for corneal health.
- Increased risk for corneal adverse events: Postmarketing experience with topical NSAIDs suggests that complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may increase the risk for corneal adverse events, which may become sight threatening; use with caution in these patients.
- Risk and severity of corneal adverse events: Postmarketing experience with topical NSAIDs also suggests that use more than 1 day prior to surgery or use beyond 14 days post-surgery may increase patient risk and severity of corneal adverse events.
- Delayed healing: Topical NSAIDs may slow or delay healing, and concomitant topical corticosteroids, which also delay healing, may increase the potential for healing problems.
- Increased bleeding time: With some NSAIDs, including NEVANAC 0.1%, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation, and there have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphema) in conjunction with ocular surgery. Use with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.
- Contact lens wear: Not to be administered while contact lenses are worn.
- Contamination of the product: Tip contact with the eye or surrounding structures could contaminate the tip with common bacteria known to cause ocular infections, and serious damage to the eye and subsequent loss of vision may result from using contaminated solutions. Use of the same bottle for both eyes is not recommended with topical eye drops that are used in association with surgery.
Common Side Effects
The most frequently reported ocular adverse reactions after cataract surgery were capsular opacity, decreased visual acuity, foreign body sensation, increased IOP, and sticky sensation, in approximately 5% to 10% of patients. Other ocular adverse reactions, at an incidence of approximately 1% to 5%, included conjunctival edema, corneal edema, dry eye, lid margin crusting, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, photophobia, tearing, and vitreous detachment; some may be the consequence of the cataract surgical procedure. Non-ocular adverse reactions reported at an incidence of 1% to 4% included headache, hypertension, nausea/vomiting, and sinusitis.
Pregnancy: Category C; reproduction studies in rabbits and rats at oral doses up to 10 mg/kg/day revealed no evidence of teratogenicity despite maternal toxicity, but in rats maternally toxic doses greater than or equal to 10 mg/kg were associated with dystocia, increased post-implantation loss, reduced fetal weights and growth, and reduced fetal survival, and nepafenac crosses the placental barrier in rats. There are no adequate and well-controlled studies in pregnant women; use only if the potential benefit justifies the potential risk to the fetus, and avoid use during late pregnancy because prostaglandin biosynthesis inhibiting drugs affect the fetal cardiovascular system (closure of the ductus arteriosus).
Lactation: Excreted in the milk of lactating rats; human milk excretion unknown, so use caution in a nursing woman.
Safety and effectiveness not established below age 10.